BACKGROUND: Increasing age is a significant risk factor for prostate cancer. The prostate is exposed to environmental and endogenous stress that may underlie this remarkable incidence. DNA methylation, genomic imprinting, and histone modifications are examples of epigenetic factors known to undergo change in the aging and cancerous prostate. In this review we examine the data linking epigenetic alterations in the prostate with aging to cancer development. METHODS: An online search of current and past peer reviewed literature on epigenetic changes with cancer and aging was performed. Relevant articles were analyzed. RESULTS: Epigenetic changes are responsible for modifying expression of oncogenes and tumor suppressors. Several of these changes may represent a field defect that predisposes to cancer development. Focal hypermethylation occurs at CpG islands in the promoters of certain genes including GSTP1, RARβ2, and RASSF1A with both age and cancer, while global hypomethylation is seen in prostate cancer and known to occur in the colon and other organs. A loss of genomic imprinting is responsible for biallelic expression of the well-known Insulin-like Growth Factor 2 (IGF2) gene. Loss of imprinting (LOI) at IGF2 has been documented in cancer and is also known to occur in benign aging prostate tissue marking the presence of cancer. Histone modifications have the ability to dictate chromatin structure and direct gene expression. CONCLUSIONS: Epigenetic changes with aging represent molecular mechanisms to explain the increased susceptibly of the prostate to develop cancer in older men. These changes may provide an opportunity for diagnostic and chemopreventive strategies given the epigenome can be modified.
BACKGROUND: Increasing age is a significant risk factor for prostate cancer. The prostate is exposed to environmental and endogenous stress that may underlie this remarkable incidence. DNA methylation, genomic imprinting, and histone modifications are examples of epigenetic factors known to undergo change in the aging and cancerous prostate. In this review we examine the data linking epigenetic alterations in the prostate with aging to cancer development. METHODS: An online search of current and past peer reviewed literature on epigenetic changes with cancer and aging was performed. Relevant articles were analyzed. RESULTS: Epigenetic changes are responsible for modifying expression of oncogenes and tumor suppressors. Several of these changes may represent a field defect that predisposes to cancer development. Focal hypermethylation occurs at CpG islands in the promoters of certain genes including GSTP1, RARβ2, and RASSF1A with both age and cancer, while global hypomethylation is seen in prostate cancer and known to occur in the colon and other organs. A loss of genomic imprinting is responsible for biallelic expression of the well-known Insulin-like Growth Factor 2 (IGF2) gene. Loss of imprinting (LOI) at IGF2 has been documented in cancer and is also known to occur in benign aging prostate tissue marking the presence of cancer. Histone modifications have the ability to dictate chromatin structure and direct gene expression. CONCLUSIONS: Epigenetic changes with aging represent molecular mechanisms to explain the increased susceptibly of the prostate to develop cancer in older men. These changes may provide an opportunity for diagnostic and chemopreventive strategies given the epigenome can be modified.
Authors: H Kamiyama; K Suzuki; T Maeda; K Koizumi; Y Miyaki; S Okada; Y J Kawamura; J K Samuelsson; S Alonso; F Konishi; M Perucho Journal: Oncogene Date: 2012-02-06 Impact factor: 9.867
Authors: Carlos Guerrero-Bosagna; Trevor R Covert; Md M Haque; Matthew Settles; Eric E Nilsson; Matthew D Anway; Michael K Skinner Journal: Reprod Toxicol Date: 2012-10-02 Impact factor: 3.143
Authors: Turang E Behbahani; Philip Kahl; Johannes von der Gathen; Lukas C Heukamp; Claudia Baumann; Ines Gütgemann; Bernhard Walter; Ferdinand Hofstädter; Patrick J Bastian; Alexander von Ruecker; Stefan C Müller; Sebastian Rogenhofer; Jörg Ellinger Journal: BMC Urol Date: 2012-03-13 Impact factor: 2.264
Authors: Victoria K Cortessis; Duncan C Thomas; A Joan Levine; Carrie V Breton; Thomas M Mack; Kimberly D Siegmund; Robert W Haile; Peter W Laird Journal: Hum Genet Date: 2012-06-28 Impact factor: 4.132
Authors: Kimberly P Keil; Lisa L Abler; Helene M Altmann; Zunyi Wang; Peiqing Wang; William A Ricke; Dale E Bjorling; Chad M Vezina Journal: Am J Physiol Renal Physiol Date: 2015-04-08
Authors: Amanda B Trombini; Claudinéia Cs Franco; Rosiane A Miranda; Júlio C de Oliveira; Luiz F Barella; Kelly V Prates; Aline A de Souza; Audrei Pavanello; Ananda Malta; Douglas L Almeida; Laize P Tófolo; Kesia P Rigo; Tatiane As Ribeiro; Gabriel S Fabricio; Juliane R de Sant'Anna; Marialba Aa Castro-Prado; Helenir Medri de Souza; Hely de Morais; Paulo Cf Mathias Journal: Cancer Biol Ther Date: 2015-05-29 Impact factor: 4.742
Authors: Sachin Bhusari; Arun R Pandiri; Hiroaki Nagai; Yu Wang; Julie Foley; Hue-Hua L Hong; Thai-Vu Ton; Michael DeVito; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; David E Malarkey; Michelle J Hooth; Robert C Sills; Mark J Hoenerhoff Journal: Toxicol Pathol Date: 2015-08-18 Impact factor: 1.902
Authors: Alan W Partin; Leander Van Neste; Eric A Klein; Leonard S Marks; Jason R Gee; Dean A Troyer; Kimberly Rieger-Christ; J Stephen Jones; Cristina Magi-Galluzzi; Leslie A Mangold; Bruce J Trock; Raymond S Lance; Joseph W Bigley; Wim Van Criekinge; Jonathan I Epstein Journal: J Urol Date: 2014-04-18 Impact factor: 7.450